Articles tagged with Enzyme Inhibitors
Researchers at The Scripps Research Institute develop a new drug-discovery strategy using click chemistry to create a potent inhibitor against the enzyme acetylcholinesterase. This breakthrough allows the target enzyme to select and catalyze its own synthesis, resulting in a highly effective treatment for Alzheimer's disease.
Researchers found that continuous ACE inhibitor users had a lower average decline in muscle strength and walking speed compared to intermittent users of other antihypertensive drugs. The study suggests that ACE inhibitors could be used to slow physical decline in elderly people without congestive heart failure.
A new study published in the Archives of Internal Medicine shows that patients with heart failure can tolerate higher doses of ACE inhibitors without severe side effects. The research found that nearly all patients experienced only slight decreases in blood pressure and kidney function, which can be managed by adjusting the dose.
Researchers found that calcium channel blockers (CCBs) were significantly less effective at preventing heart attacks, heart failure, and cardiovascular events compared to ACE inhibitors, beta-blockers, and diuretics. The study analyzed over 27,000 patients and showed a 26% higher risk of heart attack among CCB users.
A Duke University Medical Center study found that ACE inhibitors are prescribed in just over half the cases they should be, despite clear evidence of their benefits. The study's author suggests increasing physician education and implementing an oversight system to ensure patients receive the best treatments.
A University of Pennsylvania study suggests that taking ibuprofen before aspirin can inhibit the cardioprotective benefits gained from a daily aspirin regimen. The study found no competitive interaction between aspirin and Tylenol or Vioxx when taken separately.
A study by the NIH found that ACE inhibitors and beta blockers significantly reduced kidney failure risk compared to calcium channel blockers. High blood pressure management has improved stroke and heart disease risks, but kidney failure remains a concern for African Americans.
Researchers at the University of Michigan have discovered a powerful new antibiotic candidate, PD 404182, which is 10,000 times more effective than other known inhibitors of a key enzyme in Gram-negative bacteria. The compound targets KDO 8-P synthase, essential for bacterial cell surface formation, and shows promise in weakening bacte...
Researchers discover that nerve cells use chemical scissors to clip off axon guidance receptors, controlling their navigation in the nervous system. Metalloprotease inhibitors enhance netrin activity by blocking receptor cleavage.
A UI-led study found that flavopiridol, a cancer treatment, blocks HIV-1 replication in cell culture experiments at very low concentrations. This suggests the drug may have anti-HIV properties and could be a potential treatment for AIDS.
Researchers developed an experimental drug that reversed the effects of Fabry disease in mice, reducing glycolipid levels and eliminating toxic side effects. The treatment has potential applications for other lysosomal storage diseases affecting thousands of people in the US.
Omapatrilat, a vasopeptidase inhibitor, has been shown to improve cardiovascular function and reduce death rates and hospitalization for worsening heart failure. The drug may offer a potential breakthrough in treating congestive heart failure, which kills over 44,000 annually.
A study of 30 people with iron deficiency anemia found that curing Helicobacter pylori reversed the anemia. Meanwhile, researchers discovered that 51% of eligible elderly patients hospitalized with acute myocardial infarction did not receive early beta-blocker therapy, leading to higher in-hospital mortality rates.
Researchers at Thomas Jefferson University and Oxford University have found a promising drug against the hepatitis C virus (HCV), called N-nonyl-DNJ, which inhibits the activity of an important cellular enzyme, glucosidase. This drug may sidestep resistant viruses, a major problem with current treatments.
Scientists at Vanderbilt University Medical Center have identified a new target for drugs that inhibit tumor angiogenesis. Thromboxane A2 receptor antagonists show promise in blocking endothelial cell migration and preventing blood vessel formation associated with tumors.
Researchers at UCLA and Human Genome Sciences have discovered two human proteins, METH-1 and METH-2, that inhibit blood vessel formation and show promise in treating a range of cancer tumors. The proteins were found to be more potent than endostatin in preventing new blood vessel growth.
The report in Science reveals the x-ray crystal structure of MMP-2, a key target for anti-cancer drug candidates. The elucidated structure provides valuable information on the function and regulation of MMP-2, enabling the design of improved inhibitors.
Researchers at Schering-Plough Research Institute have made the first atomic view of a promising new class of cancer-fighting drugs. The discovery may lead to faster, better refinement of the drugs and the development of more potent, less toxic treatments.
Researchers found that COX-2 inhibitors suppress prostacyclin, a hormone-like substance produced in blood vessels, which can lead to increased thrombosis risk. This discovery raises concerns about the potential cardiovascular risks of these new pain relievers.
UB researchers found that a minor plant-based fat called B-sitosterol enhances an intracellular signaling system that tells cells not to divide, inhibiting prostate-cancer cell growth. The study showed a 28% inhibition of cancer-cell growth after five days in vitro.
Researchers found distinct patterns of gene expression linking cognitive control regions to stress control regions in laboratory animals. The study suggests that the brain controls stress responses through inhibition, rather than excitation, and may lead to the development of future stress intervention strategies.
A national study finds that doctors are increasingly prescribing ACE inhibitors to heart attack patients, but still underprescribing them to those most in need. The study suggests that following American College of Cardiology guidelines could have saved up to 1,800 lives in the first year.
Fibrates, used for decades to treat hyperlipidemia and atherosclerosis, have been shown to reduce inflammation in vascular muscle cells, inhibiting the production of pro-inflammatory cytokines. This mechanism suggests that fibrates may have a beneficial vascular action during atherosclerosis treatment.
Researchers found that aspirin inhibits angiogenesis in tumor cells by blocking COX-2 enzyme production, which prevents the formation of blood vessels. Additionally, aspirin also targets COX-1 enzyme in endothelial cells, forming new blood vessels.
Researchers at Jefferson Medical College have found a way to inhibit the hepatitis B virus by blocking its envelope creation, resulting in a dramatic drop in viral levels. The discovery may provide new leads for treating chronic HBV and HCV infections in humans.
Researchers have made rapid progress on a new class of anti-cancer drugs that target the Ras protein activation pathway, which causes up to 90% of pancreatic cancers. Laboratory studies have shown effective inhibition of cancer cells using FTase inhibitors.
The study reveals human beta-tryptase is a ring-like tetramer with active sites facing a central pore. Its unique architecture explains many of its distinct biochemical properties and will facilitate understanding of its role in health and disease.
A recent MGH study found that only 31% of patients with heart failure were prescribed ACE inhibitors in 1994, despite their proven effectiveness in reducing death and disability. The study suggests a lack of knowledge and unrealistic assessments may contribute to the underprescription of these medications.
Research shows that the tannins produced by oak trees inhibit gypsy moth caterpillar growth and viral infection, with enzymes like PPO playing a key role in this process. This discovery could lead to new methods for controlling gypsy moth populations.
A recent study found that inhibiting the ICE gene, responsible for programmed cell death, slowed ALS-like symptoms in mice. The research suggests that targeting this genetic pathway could lead to a new treatment option for patients with ALS.